Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers
Conclusion: HC-ER can be administered without regard to meals. While there was no evidence of "dose-dumping" (an unintended, rapid release in a short time period of all or most of the hydrocodone from HC-ER), even with 40% alcohol, as with all opioids, alcohol should not be ingested while using HC-ER. Keywords: opioid, food interaction, alcohol interaction, bioavailability, norhydrocodone, hydromorphone (Source: International Journal of COPD)
Source: International Journal of COPD - January 19, 2015 Category: Respiratory Medicine Tags: Clinical Pharmacology: Advances and Applications Source Type: research
Effects of food and alcohol on pharmacokinetics of hydrocodone ER
Farr SJ, Robinson CY, Rubino CM (Source: International Journal of COPD)
Source: International Journal of COPD - January 18, 2015 Category: Respiratory Medicine Source Type: research
Enantiomer-selective pharmacokinetics, oral bioavailability, and sex effects of various alpha-lipoic acid dosage forms
Robert Hermann,1 Julius Mungo,2 Peter Jürgen Cnota,2 Dan Ziegler3 1Clinical Research Appliance (cr appliance), Gelnhausen, Germany; 2MEDA Pharma GmbH & Co KG, Bad Homburg, Germany; 3Institute for Clinical Diabetology, German Diabetes Center, Heinrich Heine University, Düsseldorf, Germany Abstract: The present study aimed to examine the enantiomer-selective pharmacokinetics (PK), relative bioavailability (Frel), and sex effects of various oral dosage forms of racemic alpha-lipoic acid (ALA). In an open-label, randomized, four-period, four-sequence crossover study, 24 healthy adult subjects (12 males and 12 fe...
Source: International Journal of COPD - November 28, 2014 Category: Respiratory Medicine Tags: Clinical Pharmacology: Advances and Applications Source Type: research
Alpha-lipoic acid enantiomers
Hermann R, Mungo J, Cnota PJ, Ziegler D (Source: International Journal of COPD)
Source: International Journal of COPD - November 27, 2014 Category: Respiratory Medicine Source Type: research
Parkinson & #39;s disease: carbidopa, nausea, and dyskinesia
(Source: International Journal of COPD)
Source: International Journal of COPD - November 14, 2014 Category: Respiratory Medicine Tags: Clinical Pharmacology: Advances and Applications Source Type: research
Parkinson's disease: carbidopa, nausea, and dyskinesia
Marty Hinz,1 Alvin Stein,2 Ted Cole3 1Clinical Research, NeuroResearch Clinics, Cape Coral, FL, 2Stein Orthopedic Associates, Plantation, FL, 3Cole Center for Healing, Cincinnati, OH, USA Abstract: When ʟ-dopa use began in the early 1960s for the treatment of Parkinson's disease, nausea and reversible dyskinesias were experienced as continuing side effects. Carbidopa or benserazide was added to ʟ-dopa in 1975 solely to control nausea. Subsequent to the increasing use of carbidopa has been the recognition of irreversible dyskinesias, which have automatically been attributed to ʟ-dopa. The research int...
Source: International Journal of COPD - November 14, 2014 Category: Respiratory Medicine Tags: Clinical Pharmacology: Advances and Applications Source Type: research
Parkinson's disease: carbidopa, nausea, and dyskinesia
Hinz M, Stein A, Cole T (Source: International Journal of COPD)
Source: International Journal of COPD - November 13, 2014 Category: Respiratory Medicine Source Type: research
A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban
Conclusion: Apixaban 2.5 mg BID demonstrated less intersubject variability in exposure, lower AXA AUC, and higher trough and smaller peak-to-trough fluctuations in plasma concentration and AXA, suggesting more constant anticoagulation compared with rivaroxaban 10 mg QD. However, the clinical impact of these differences on the relative efficacy and safety of apixaban and rivaroxaban remains to be determined. Keywords: apixaban, pharmacodynamics, pharmacokinetics, rivaroxaban, safetyA letter to the Editor has been received and published for this article. (Source: International Journal of COPD)
Source: International Journal of COPD - November 13, 2014 Category: Respiratory Medicine Tags: Clinical Pharmacology: Advances and Applications Source Type: research
PK PD of apixaban and rivaroxaban in healthy subjects
Frost C, Song Y, Barrett YC, Wang J, Pursley J, Boyd RA, LaCreta F (Source: International Journal of COPD)
Source: International Journal of COPD - November 12, 2014 Category: Respiratory Medicine Source Type: research
Evaluating the effects of dexmedetomidine compared to propofol as adjunctive therapy in patients with alcohol withdrawal
Conclusion: In patients with severe AW who require sedation, both dexmedetomidine and propofol have unique and advantageous properties. Both agents appear to have equivalent efficacy in reducing AW-related symptoms and benzodiazepine and haloperidol requirements. These results should be validated in a larger, prospective trial. Keywords: dexmedetomidine, propofol, benzodiazepines, alcohol, withdrawal (Source: International Journal of COPD)
Source: International Journal of COPD - October 31, 2014 Category: Respiratory Medicine Tags: Clinical Pharmacology: Advances and Applications Source Type: research
